Rucaparib治疗携带BRCA1或BRCA2基因改变的转移性去势抵抗性前列腺癌男性患者
TRITON2 II期研究纳入115例携带BRCA改变的mCRPC患者,接受rucaparib 600mg每日两次治疗。独立影像评估确认的ORR为43.5%,研究者评估为50.8%,PSA应答率为54.8%。rucaparib具有抗肿瘤活性,安全性可控。
要点
- BRCA改变的mCRPC患者接受rucaparib后独立影像确认ORR达43.5%。
- 确认的PSA应答率为54.8%,BRCA2改变者PSA应答率更高。
- 最常见≥3级治疗相关不良事件为贫血(25.2%)。
核心结论
- Rucaparib在携带致病性BRCA改变的mCRPC患者中具有抗肿瘤活性,安全性可控。
研究设计与样本
- II期TRITON2研究纳入既往接受过1-2线雄激素受体靶向治疗和1种紫杉类化疗后进展的mCRPC患者。
- 疗效和安全性人群为115例携带致病性BRCA改变且至少接受1剂rucaparib(600mg每日两次)的患者。
主要发现
- 独立影像评估确认的ORR为43.5%(95%CI 31.0%-56.7%,27/62),研究者评估为50.8%(95%CI 38.1%-63.4%,33/65)。
- 确认的PSA应答率为54.8%(95%CI 45.2%-64.1%,63/115)。
- 胚系或体细胞BRCA改变以及BRCA1或BRCA2改变的患者ORR相似,BRCA2改变者PSA应答率更高。
- 最常见的≥3级治疗中出现的不良事件为贫血(25.2%,29/115)。
临床怎么用
- 对于既往接受过雄激素受体靶向治疗和紫杉类化疗的BRCA改变mCRPC患者,可考虑使用rucaparib。
- 治疗期间需监测贫血等不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: BRCA1 or BRCA2 (BRCA) alterations are common in men with metastatic castration-resistant prostate cancer (mCRPC) and may confer sensitivity to poly(ADP-ribose) polymerase inhibitors. We present results from patients with mCRPC associated with a BRCA alteration treated with rucaparib 600 mg twice daily in the phase II TRITON2 study. METHODS: We enrolled patients who progressed after one to two lines of next-generation androgen receptor-directed therapy and one taxane-based chemotherapy for mCRPC. Efficacy and safety populations included patients with a deleterious BRCA alteration who received ≥ 1 dose of rucaparib. Key efficacy end points were objective response rate (ORR; per RECIST/Prostate Cancer Clinical Trials Working Group 3 in patients with measurable disease as assessed by blinded, independent radiology review and by investigators) and locally assessed prostate-specific antigen (PSA) response (≥ 50% decrease from baseline) rate. RESULTS: Efficacy and safety populations included 115 patients with a BRCA alteration with or without measurable disease. Confirmed ORRs per independent radiology review and investigator assessment were 43.5% (95% CI, 31.0% to 56.7%; 27 of 62 patients) and 50.8% (95% CI, 38.1% to 63.4%; 33 of 65 patients), respectively. The confirmed PSA response rate was 54.8% (95% CI, 45.2% to 64.1%; 63 of 115 patients). ORRs were similar for patients with a germline or somatic BRCA alteration and for patients with a BRCA1 or BRCA2 alteration, while a higher PSA response rate was observed in patients with a BRCA2 alteration. The most frequent grade ≥ 3 treatment-emergent adverse event was anemia (25.2%; 29 of 115 patients). CONCLUSION: Rucaparib has antitumor activity in patients with mCRPC and a deleterious BRCA alteration, but with a manageable safety profile consistent with that reported in other solid tumor types.
引用
- Abida W, Patnaik A, Campbell D, et al. Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration. J Clin Oncol. 2020. PMID: 32795228. doi:10.1200/JCO.20.01035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。